Новые возможности терапии диссеминированного колоректального рака
К. С. КуриловО В ЖарковаЕ. Б. МироноваГ К ЖерловВ. А. ХайленкоLev DemidovТ. А. КузнецоваА. В. СизинцевС. В. СтражевVera Karaseva
0
Citation
0
Reference
0
Related Paper
Abstract:
Efficacy of three chemotherapy regimens was studied in 99 patients with metastatic colorectal cancer. Patients receiving oxaliplatin plus capecitabine combination demonstrated better immediate and follow-up results than those receiving oxaliplatin + fluorouracil + folinic acid or fluorouracil + folinic acid regimens. Overall response and 2-year survival rates were 45.5±8.6%and19.1%respectivelyinoxaliplatinpluscapecit-8.6% and 19.1% respectively in oxaliplatin plus capecitabine group versus 40.6±8.7and16.3%respectivelyinthefluorouracil+folinicacidgroup.Differencesin.7 and 16.3% respectively in the fluorouracil + folinic acid group. Differences in survival rates between groups with vs without oxaliplatin were statistically significant (pKeywords:
Folinic acid
Cite